Everolimus
Top View
- WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
- Combined Low-Dose Everolimus and Low-Dose Tacrolimus
- Peripheral T-Cell Lymphoma: Pharmacotherapy Overview
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Solving the Puzzle of Treatment Resistance in Patients with HER2-Positive Metastatic Breast Cancer – New Approaches to HER Target Family Network
- Afinitor, INN-Everolimus
- HER2-Positive Advanced Breast Cancer: Optimizing Patient Outcomes and Opportunities for Drug Development
- CTAC Meeting Minutes, July 10, 2013
- Different Immunological Effects of the Molecular Targeted Agents Sunitinib, Everolimus and Temsirolimus in Patients with Renal Cell Carcinoma
- New Drugs Approved in FY 2019
- Mtor Signaling in Cancer and Mtor Inhibitors in Solid Tumor Targeting Therapy
- Tashanna K. Myers, MD, FACOG, FACS
- The State-Of-The-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
- A Phase II Study of Everolimus in Patients with Advanced Solid Malignancies with TSC1, TSC2, NF1, NF2 Or STK11 Mutations
- Clinical Protocol a Phase 1B, Open Label, Dose Finding Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitin
- 2014 San Antonio Breast Cancer Symposium Review HER2‐Positive Disease
- Tolerogenic Nanoparticles Restore the Antitumor Activity of Recombinant
- Open Full Page